<div><div></div><div><span><ul><li><span>According to estimates from 11 analysts, Sutro Biopharma, Inc. stock's average price target has risen from $35.73 to $41.64, with forecasts ranging from $9 to $60 per share</span></li><li><span>Based on the May 14 closing price, the updated target implies approximately 8% potential upside</span></li><li><span>Consensus rating remains at “Buy” across 12 covering analysts, with 11 Buys, 0 Holds and 1 Sells</span></li></ul><p><span>Explore more price target data and ratings for Sutro Biopharma, Inc. on the </span><span>, and track all previous and future analyst recommendations for Sutro Biopharma, Inc. in the dedicated </span>News Flow<span>.</span></p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.</span></div></section></span></div></div>

STRO

ARKG

<p>Sutro Biopharma, Inc.'s stock price target has been raised to $43.64, indicating a potential upside of 14%. Analysts' estimates show an average target increase from $35.73 to $41.64, with a consensus rating of 'Buy' from 12 analysts, including 11 Buys and 1 Sell.</p>

TradingView

Sutro Biopharma

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

VanEck Biotech ETF

ALPS Medical Breakthrough

Health Care Select Sector SPDR

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

VG Health

iShares US Pharma

Factset Research

Sutro Biopharma, Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 14% Upside